Who are BAY 59-7939's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Hympavzi, Eliquis, Xarelto, Heparin Sodium In Plastic Container, Low dose nadroparin, Edoxaban plus Single Antiplatelet Agent.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bay-59-7939.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

BAY 59-7939 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BAY 59-7939 (BAY 59-7939) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct Factor Xa inhibitor. Area: Cardiovascular.

phase 3 Direct Factor Xa inhibitor Factor Xa Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

BAY 59-7939 (BAY 59-7939) — Bayer. BAY 59-7939 is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent thrombus formation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BAY 59-7939 TARGET	BAY 59-7939	Bayer	phase 3	Direct Factor Xa inhibitor	Factor Xa
Hympavzi	MARSTACIMAB	Pfizer Inc	marketed	Monoclonal Antibody	Factor Xa	2025-01-01
Eliquis	apixaban	Bristol-Myers Squibb	marketed	Factor Xa inhibitor	Factor Xa (FXa)	2012-01-01
Xarelto	rivaroxaban	Johnson & Johnson	marketed	Direct Factor Xa Inhibitor	Factor Xa (FXa)	2011-01-01
Heparin Sodium In Plastic Container	Heparin Sodium	Fresenius Kabi	marketed	Anti-coagulant	Antithrombin III, Factor Xa, Factor IIa	1939-01-01
Low dose nadroparin	Low dose nadroparin	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	marketed	Low-molecular-weight heparin (LMWH)	Factor Xa, Thrombin (Factor IIa)
Edoxaban plus Single Antiplatelet Agent	Edoxaban plus Single Antiplatelet Agent	Gi-Byoung Nam	marketed	Factor Xa inhibitor + antiplatelet agent combination	Factor Xa (edoxaban component); P2Y12 or COX-1 (antiplatelet component, depending on agent)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2034-02-17 — Xarelto · 9539218 · Method of Use · US
2034-08-17 — Xarelto · 9539218*PED · Compound · US

Sponsor landscape (Direct Factor Xa inhibitor class)

Ahmed AbdelMoneim Hassan Ali · 1 drug in this class
Bayer · 1 drug in this class
Chang Gung Memorial Hospital · 1 drug in this class
Charles University, Czech Republic · 1 drug in this class
Daiichi Sankyo Co., Ltd. · 1 drug in this class
Florida Orthopaedic Institute · 1 drug in this class
McMaster University · 1 drug in this class
Rennes University Hospital · 1 drug in this class
Swiss Paraplegic Research, Nottwil · 1 drug in this class
Taejoon Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BAY 59-7939 — Competitive Intelligence Brief. https://druglandscape.com/ci/bay-59-7939. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing